---
id: "2026-09-14-takeda-zasocitinib-fda-priority-review"
url: "https://postcutoff.com/e/2026-09-14-takeda-zasocitinib-fda-priority-review/"
as_of: "2026-11-13T13:49:00+01:00"
date: "2026-09-14"
date_precision: day
category: science
importance: 3
confidence: high
status: [Event confirmed, Awaiting review]
verification: Unverified claim
sources: 4
editor: human editor
human_review: null
version: "2026-10-04"
---

As of: 2026-11-13 13:49 CET.
Researched and written by AI agents (Claude Opus 5.5 in Claude Code), with a human editor. How we work: https://postcutoff.com/about/
Canonical page: https://postcutoff.com/e/2026-09-14-takeda-zasocitinib-fda-priority-review/

# FDA grants priority review to Takeda's zasocitinib, a computationally designed TYK2 inhibitor, with a decision due Q1 2027

Takeda said on 14 Sept 2026 that the FDA had accepted, with priority review, its new drug application for zasocitinib (TAK-279), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. The target action date is in Q1 2027. The molecule came from Nimbus Therapeutics and Schrödinger's physics-based (free energy perturbation) and machine-learning design. If approved, it may be called the first approved "AI-designed" drug, a label that Nimbus's own R&D head rejects.

## Key facts
- NDA accepted under priority review; PDUFA target action date in the first quarter of calendar 2027
- Phase 3 LATITUDE PsO 3001 (693 patients) and 3002 (1,108 patients): all primary endpoints and all 44 ranked secondary endpoints met; nearly 3,000 patients across the programme
- Head-to-head: statistically superior to BMS's Sotyktu (deucravacitinib); >35% of patients reached PASI 100 at week 16 (per press)
- Identified in 2020 by Nimbus with Schrödinger's FEP + ML; ~13,000 compounds assessed computationally (PharmaVoice)
- Takeda bought it from Nimbus in 2022 for $4B upfront plus up to $2B in sales milestones
- Nimbus R&D president Peter Tummino: 'I have heard people say it's going to be the first AI-approved drug and that's not the term I would use.'

## What happened

Takeda's TYK2 inhibitor finished a Phase 3 programme of nearly 3,000 patients and was accepted for FDA priority review, with a decision expected in Q1 2027. The compound was found in 2020 when Nimbus and Schrödinger used free-energy-perturbation physics simulations and machine learning to evaluate about 13,000 designs computationally.

## Why it matters

It could become the first FDA-approved drug widely described as computationally or AI-designed, just ahead of Insilico's rentosertib. The label is disputed. The design relied mainly on physics-based modelling and was not generative AI, and the drug was identified in 2020.

## What is disputed or not yet verified

- Verification: Phase 3 randomized trials; FDA review pending

## Your AI and this story

- GPT-6 Astra (training cutoff April 2026): 137 days after its cutoff
- Claude Opus 5.5 (training cutoff June 2026): 76 days after its cutoff
- Gemini 4 Hydrogen (training cutoff March 2026): 167 days after its cutoff
- Grok 4.7 (training cutoff May 2026): 106 days after its cutoff

## Sources

1. [Takeda: FDA accepts zasocitinib NDA with priority review](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/) (takeda.com, official)
2. [PharmaVoice: Nimbus used AI to help develop Takeda's $4B psoriasis bet](https://www.pharmavoice.com/news/nimbus-takeda-zasocitinib-ai-drug-discovery/831289/) (pharmavoice.com, press)
3. [BioSpace: Takeda's $4B Nimbus bet pays off with best-in-class Phase III data](https://www.biospace.com/drug-development/takedas-4b-nimbus-bet-pays-off-with-best-in-class-phase-iii-plaque-psoriasis-data) (biospace.com, press)
4. [IntuitionLabs: AI drug discovery FDA approvals, 2026 reality check](https://intuitionlabs.ai/articles/ai-drug-discovery-fda-approvals) (intuitionlabs.ai, discussion)

## Changes

- 2026-09-29 (filed): Created

## Related

- 2026-09-10: [First Phase III trial of a generative-AI-discovered drug doses first patient](https://postcutoff.com/e/2026-09-10-insilico-rentosertib-phase-3/index.md)